SB301 amends Oklahoma’s income tax credit for donations to qualifying research institutions. The bill continues the existing credit for donations to independent biomedical research institutes and cancer research institutes, but revises the annual statewide credit caps and the per-taxpayer limits beginning in tax year 2026. For tax years 2007 through 2025, the total annual credit cap remains tied to $2 million, with the credit percentage adjusted to keep claims within that limit. Starting in 2026, the bill lowers the annual statewide cap to $1.5 million for independent biomedical research institutes and $500,000 for cancer research institutes, with separate percentage-adjustment formulas for each category.
The bill also updates the definitions of qualifying institutions. An independent biomedical research institute must be a 501(c)(3) organization in Oklahoma focused on peer-reviewed basic biomedical research, with a board, its own staff, ability to accept grants, and at least $20 million in annual NIH funding. A cancer research institute must be a tax-exempt organization focused on improving cancer clinical care in Oklahoma through peer-reviewed research and education, or a supporting organization affiliated with such an entity, and must receive at least $4 million in annual National Cancer Institute funding. The bill keeps the credit nonrefundable, allows unused credits to be carried forward for four years, and authorizes the Oklahoma Tax Commission to issue forms and administer the credit.
In practical terms, SB301 changes Oklahoma tax law by narrowing and recalibrating the fiscal exposure of the research-donation credit while preserving the incentive itself. It affects taxpayers who donate to qualifying biomedical or cancer research institutions, the institutions that can receive those donations, and the Oklahoma Tax Commission, which must administer the revised caps and formulas. The bill also updates statutory references and language and takes effect November 1, 2025.
The overall sentiment around the bill appears strongly favorable. It passed the Senate Finance Committee unanimously, cleared the Senate 43-0, advanced through House committee and subcommittee with broad support, and passed the House 88-0. That voting pattern suggests bipartisan agreement on continuing the credit and supporting research institutions, while also adjusting the program’s limits and eligibility rules.
There is little visible contention in the available record, but the main policy issue is the reduction and reallocation of the credit caps beginning in 2026. Potential points of concern would be whether the lower statewide limits could reduce donations or funding for qualifying institutes, and whether the updated funding thresholds and organizational definitions might make it harder for some entities to qualify. No committee transcript objections are available, and the recorded votes show no significant opposition.
SB301 amends 68 O.S. 2021, Section 2357.45, governing Oklahoma’s income tax credit for donations to independent biomedical research institutes and cancer research institutes. It changes the annual credit cap structure beginning in tax year 2026, revises per-taxpayer limits, and updates the qualifying definitions and funding thresholds for eligible institutions. The bill affects individual and business taxpayers making qualifying donations, the research institutions that can generate credits, and the Oklahoma Tax Commission’s administration of the program.
The bill appears to have broad bipartisan support and little recorded opposition. It passed every recorded stage overwhelmingly, including unanimous committee and floor votes in the Senate and near-unanimous support in the House. The available record suggests lawmakers generally favored preserving the research-donation credit while tightening the fiscal limits and updating eligibility standards.
The main substantive issue is the bill’s reduction of the annual credit caps starting in 2026 and the more specific allocation between biomedical and cancer research donations. Supporters likely viewed this as a way to control the tax expenditure while continuing to encourage research philanthropy. Any opposition would most likely come from donors or research institutions concerned that the lower caps, revised formulas, or higher funding thresholds could limit participation or reduce available credits, but no direct objections are reflected in the available transcripts or votes.